Sarepta Therapeutics (SRPT) Offering Seeing High Demand, Expected to Price at Modest Discount - Feurstein
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Trump, Brexit uncertainty hit stocks and dollar, gold jumps
- Noble Energy (NBL) to Acquire Clayton Williams Energy (CWEI) for $2.7B in Cash and Stock
- UnitedHealth Group (UNH) Tops Q4 EPS by 4c; Affirms Outlook
- Oil rises on weaker dollar, Saudi commitment to cut output
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Sarepta Therapeutics (NASDAQ: SRPT) offering well oversubscribed, upsized and seen pricing at a modest discount to close. - Adam Feurstein.
$SRPT latest chatter on offering: well oversubscribed, upsizing, will price at modest discount to close.— Adam Feuerstein (@adamfeuerstein) September 22, 2016
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Positive on Sarepta (SRPT) Initial Exondys Launch Metrics
- Sarepta Therapeutics (SRPT) Reported $5.4M Exondys 51 Sales
- Equity and Commodity Markets Movements
Create E-mail Alert Related CategoriesFDA, Rumors, Trader Talk
Related EntitiesAdam Feuerstein
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!